Daily Sundial

Bydureon Weight Loss Injection Review – Bydureon Bcise Exenatide Extended Release Alternatives Over the Counter

Below are 3 natural substitutes to Bydureon that can reduce body weight and control blood sugar levels. For best results it is possible to use in a stack – this means combining 2 or more products ...
Medscape

Exenatide Approved for Type 2 Diabetes: An Expert Interview With John B. Buse, MD, PhD

May 4, 2005 (updated May 5, 2005) — Editor's Note: On April 29, Amylin Pharmaceuticals, Inc., and Eli Lilly and Co. announced that the U.S. Food and Drug Administration (FDA) had approved exenatide ...
Healio

Once-weekly exenatide improved glucose control, weight loss in DURATION studies

Please provide your email address to receive an email when new articles are posted on . ORLANDO — A once-weekly injection of exenatide may be an important therapeutic option for patients with type 2 ...
FierceBiotech

Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events

SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., March 26 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (NASDAQ: AMLN) , Eli Lilly and Company (NYSE: LLY) and ...
Medscape

Once-Weekly Exenatide Okayed by FDA for T2DM After Long Look

January 27, 2012 — The US Food and Drug Administration (FDA) today approved a once-weekly extended-release formulation of exenatide injection (Bydureon, Amylin Pharmaceuticals) as an adjunct to diet ...
FierceBiotech

PRESS RELEASE: Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study

SAN DIEGO & INDIANAPOLIS & CAMBRIDGE, Mass., Oct 31, 2007 (BUSINESS WIRE) -- Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (NASDAQ: ALKS) today ...
FiercePharma

U.S. FDA Approves Bydureon® Pen (exenatide extended-release for injectable suspension) for Once-Weekly Treatment of Adults with Type 2 Diabetes

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved the Bydureon® Pen (exenatide extended-release for injectable ...
Medindia

Switching to Once-Daily Victoza(R) (Liraglutide [rDNA Origin] Injection) from Exenatide Further Improves Blood Sugar Control in Patients with Type 2 Diabetes

PRINCETON, N.J., March 30 Diabetes Care published online the results of the Novo Nordisk (NVO) LEAD(TM) 6 extension study, which evaluated the efficacy and safety of switching from exenatide, which is ...
Medindia

Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update

SAN DIEGO and INDIANAPOLIS, Nov. 2, 2009 Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today issued the following statement in response to the U.S. Food and Drug ...
FiercePharma

BYETTA® Provided Greater Glycemic Durability and Overall Glycemic Control than Amaryl® in Patients with Type 2 Diabetes

PHILADELPHIA--Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced new clinical data from the European Exenatide (EUREXA) study that showed treatment with BYETTA® (exenatide) injection resulted ...
Europa Press

Type 2 Diabetes Patients with Long-Standing Disease Achieved Glycaemic Control When BYETTA(R) (exenatide) Injection Was

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from the first double-blind, placebo-controlled clinical study to evaluate exenatide injection ...
Europa Press

Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) (exenatide) Injection Therapy: Data Presented

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a study comparing the effect of long-term treatment with either exenatide injection or ...